Received Jun 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
nerve damage that is 100 times more painful than the shingles; suspected Vaccination failure; got shingles 4 weeks ago; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) solution for injection for prophylaxis. On an unknown date, the patient received Shingles vaccine. In MAY-2026, less than a year after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: suspected Vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: got shingles 4 weeks ago). On an unknown date, the patient experienced nerve damage (Verbatim: nerve damage that is 100 times more painful than the shingles). The outcome of the vaccination failure and shingles were not reported and the outcome of the nerve damage was not resolved. It was unknown if the reporter considered the vaccination failure, shingles and nerve damage to be related to Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine. Additional Information: GSK Receipt Date: 14-JUN-2026 This case was reported by a patient via interactive digital media. The patient had received the vaccines a year ago and had developed shingles 4 weeks ago. then patient had long-term nerve damage that was 100 times more painful than the shingles. The batch number was not provided and unable to contact the reporter. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.; Sender's Comments: A case of Vaccination failure, less than a year after receiving Shingles vaccine in a patient. Case lacks further information on exact time to onset, medical history, concurrent conditions, completion of primary vaccination schedule and laboratory confirmation. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.